Block Listing Interim Review and TVR Update

RNS Number : 4416M

CVS Group plc

11 January 2023

 

11 January 2023

CVS Group plc

("CVS" or the "Company")

Block Listing Interim Review and TVR Update

CVS, one of the UK's leading providers of integrated veterinary services, makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements.  References to securities are to the Company's ordinary shares of 0.2 pence each ("Ordinary Shares").

Name of the company:		CVS Group plc
Name of relevant scheme:		1.  CVS Group plc 2017-2020 Sharesave Scheme; 2.  CVS Group plc 2018-2021 SAYE Sharesave Scheme; and 3.  CVS Group 2018 SAYE Plan
Period of return:	From:	12 July 2022	To:	11 January 2023
Balance of unallotted securities under scheme(s) from previous return:		1.  230 2.  19,598 3.  348,290
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		1.  Nil 2.  Nil 3.  Nil
Less:  Number of securities issued / allotted under scheme(s) during period:		1.  0 2.  6,734 3.  112,148
Equals: Balance under scheme(s) not yet issued / allotted at end of period:		1.  230 2.  12,864 3.  236,142
Number and class of securities originally listed and the date of admission:		1.  114,302 Ordinary Shares admitted on 11 January 2021 and 1,535 Ordinary Shares admitted on 1 September 2021 2.  296,069 Ordinary Shares admitted on 1 September 2021 3.  350,000 Ordinary Shares admitted on 30 December 2021

Total Voting Rights

The number of securities that have been issued during the block listing review period stated above includes 106,955 new Ordinary Shares issued on 10 January 2023 in connection with the exercise of employee share options under the CVS Group plc 2019-2023 SAYE Sharesave Scheme and a further 1,474 new Ordinary Shares issued on 10 January 2023 in connection with the exercise of employee options under the CVS Group plc 2018-2022 SAYE Sharesave Scheme . 

Following the issue of these new Ordinary Shares, which rank pari passu in all respects with the Company's existing Ordinary Shares, the Company has a total issued share capital of 71,380,400 Ordinary Shares, each carrying one voting right.  The Company holds no Ordinary Shares in treasury so the total number of voting rights is therefore 71,380,400.

This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.

Contacts:

CVS Group plc  via Camarco

Richard Fairman, CEO

Jenny Farrer, Company Secretary

Peel Hunt LLP (Nominated Adviser & Broker)  [phone]

Adrian Trimmings / Michael Burke / Andrew Clark / Lalit Bose

  Berenberg (Joint Broker)  [phone]

Toby Flaux / Ben Wright / Ciaran Walsh / Milo Bonser

Camarco (Financial PR) 

Geoffrey Pelham-Lane     [phone]

Ginny Pulbrook   [phone]

  Toby Strong  [phone]  

 

END

 

 

TVRBLGDBIDBDGXB